NSUP
KRYS icon

NLB Skladi upravljanje premozenja’s Krystal Biotech KRYS Stock Holding History

NLB Skladi upravljanje premozenja’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Hold
955
– – 0.01% 324
2026
Q1 		$247K Hold
955
– – 0.01% 314
2025
Q4 		$235K Buy
+955
New +$201K 0.01% 317

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NLB Skladi upravljanje premozenja's KRYS Position: Q2 2026 in Review

NLB Skladi upravljanje premozenja held its Krystal Biotech (KRYS) position steady in Q2 2026 at 955 shares worth $355K. The position accounts for 0.01% of the portfolio, ranked #324.

NLB Skladi upravljanje premozenja first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 421 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • NLB Skladi upravljanje premozenja held 955 shares of Krystal Biotech worth $355K as of Q2 2026.
  • NLB Skladi upravljanje premozenja left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up 0.01% of NLB Skladi upravljanje premozenja's portfolio in Q2 2026, its #324 holding.
  • NLB Skladi upravljanje premozenja first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 421 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on NLB Skladi upravljanje premozenja's 13F filing for Q2 2026, filed 6 Aug 2026.